GEN News Highlights

Claritas Partners with Life Tech, Lockheed to Sequence Military Veteran Exomes

(Page
1
of
1)

As part of a project that reportedly is one of the largest sequencing initiatives ever undertaken in the U.S., the Department of Veterans Affairs awarded Claritas Genomics a $9 million contract toward the exome sequencing of veteran samples including those from the Million Veteran Program (MVP) over the next 12 months.

For this project, Claritas Genomics, a genetic testing company spun out of Boston Children's Hospital earlier this year that primarily focuses on pediatric medicine, is receiving support from Life Technologies and its Ion Proton™ sequencing technology; Alvarez and Associates, which is providing technical support; and Lockheed Martin, which will be applying data security knowledge to help manage all the data that will be generated during the sequencing process.

MVP, a research program launched in 2011, is combining genetic, health, lifestyle, and military-exposure data collected from questionnaires, medical records, and genetic analyses all into a single database. MVP has more than 210,000 enrollees to date, and it is hoped that up to a million veterans in the VA study will enroll over the next five to six years.

"As a U.S. military veteran, I am proud of the fact that my company is able to serve those individuals who were/are willing to sacrifice all in service to our country," said Everett Alvarez, Jr., CEO at Alvarez & Associates, in a statement. "I feel that this effort will greatly improve our ability to understand and better assist those veterans in need as well as the future generations of veterans."

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

56.6%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.